Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.

IF 4.8 4区医学 Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-02-01 DOI:10.1080/21645515.2023.2165856

Moe H Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh, Amit Srivastava

{"title":"Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.","authors":"Moe H Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh, Amit Srivastava","doi":"10.1080/21645515.2023.2165856","DOIUrl":null,"url":null,"abstract":"<p><p>Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable programmatic resilience and can catalyze vaccine confidence and coverage. Inactivated SARS-CoV-2 vaccines are among the most widely used vaccines worldwide. This review synthesizes the available evidence identified as of May 26, 2022, on the safety, immunogenicity, and effectiveness of a heterologous BNT162b2 (Pfizer-BioNTech) mRNA vaccine booster dose after an inactivated SARS-CoV-2 vaccine primary series, to help protect against COVID-19. Evidence showed that the heterologous BNT16b2 mRNA vaccine booster enhances immunogenicity and improves vaccine effectiveness against COVID-19, and no new safety concerns were identified with heterologous inactivated primary series with mRNA booster combinations.</p>","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2165856"},"PeriodicalIF":4.8000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/49/KHVI_19_2165856.PMC9980688.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21645515.2023.2165856","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable programmatic resilience and can catalyze vaccine confidence and coverage. Inactivated SARS-CoV-2 vaccines are among the most widely used vaccines worldwide. This review synthesizes the available evidence identified as of May 26, 2022, on the safety, immunogenicity, and effectiveness of a heterologous BNT162b2 (Pfizer-BioNTech) mRNA vaccine booster dose after an inactivated SARS-CoV-2 vaccine primary series, to help protect against COVID-19. Evidence showed that the heterologous BNT16b2 mRNA vaccine booster enhances immunogenicity and improves vaccine effectiveness against COVID-19, and no new safety concerns were identified with heterologous inactivated primary series with mRNA booster combinations.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新冠肺炎mRNA疫苗BNT162b2在灭活SARS-CoV-2病毒疫苗后作为异源加强剂的疫苗有效性的证据合成和汇总分析。

引入新冠肺炎初级疫苗接种有助于减少由SARS-CoV-2感染引起的严重疾病和死亡。了解异源加强方案所赋予的保护为替代疫苗接种策略提供了信息，这些策略能够实现计划复原力，并能够促进疫苗的信心和覆盖率。灭活的严重急性呼吸系统综合征冠状病毒2型疫苗是世界上使用最广泛的疫苗之一。本综述综合了截至2022年5月26日确定的关于异源BNT162b2（Pfizer-BioNTech）mRNA疫苗加强剂在灭活的SARS-CoV-2疫苗初级系列后的安全性、免疫原性和有效性的现有证据，以帮助预防新冠肺炎。有证据表明，异源BNT16b2 mRNA疫苗加强剂增强了免疫原性，提高了疫苗对新冠肺炎的有效性，并且没有发现具有mRNA加强剂组合的异源灭活初级系列存在新的安全问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY

自引率

8.30%

发文量

审稿时长

1 months

期刊介绍： (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.